IKNAIkena Oncology, Inc.

Nasdaq ikenaoncology.com


$ 1.40 $ 0.06 (4.87 %)    

Thursday, 16-May-2024 15:59:55 EDT
QQQ $ 451.64 $ -0.92 (-0.2 %)
DIA $ 399.14 $ -0.07 (-0.02 %)
SPY $ 528.49 $ -1.09 (-0.21 %)
TLT $ 92.06 $ -0.09 (-0.1 %)
GLD $ 220.06 $ -0.86 (-0.39 %)
$ 1.4
$ 1.33
$ 0.00 x 0
$ 0.00 x 0
$ 1.33 - $ 1.40
$ 1.02 - $ 7.38
211,061
na
67.56M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-12-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-reiterates-outperform-on-ikena-oncology-maintains-8-price-target

Wedbush analyst David Nierengarten reiterates Ikena Oncology (NASDAQ:IKNA) with a Outperform and maintains $8 price target.

 ikena-oncology-q1-eps-033-beats-041-estimate

Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.41...

 hc-wainwright--co-reiterates-buy-on-ikena-oncology-maintains-11-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $11 price ...

 hc-wainwright--co-maintains-buy-on-ikena-oncology-maintains-11-price-target

HC Wainwright & Co. analyst Andres Maldonado maintains Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $11 price t...

 ikena-oncology-q4-eps-041-beats-043-estimate-sales-65800k-miss-314m-estimate

Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.43...

 ikena-oncology-refocuses-on-key-programs-analysts-maintain-outperform-ratings-amid-strategic-organizational-changes

Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workf...

 wedbush-reiterates-outperform-on-ikena-oncology-maintains-8-price-target

Wedbush analyst David Nierengarten reiterates Ikena Oncology (NASDAQ:IKNA) with a Outperform and maintains $8 price target.

 hc-wainwright--co-reiterates-buy-on-ikena-oncology-maintains-11-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $11 price ...

 ikena-oncology-outlines-key-priorities-and-provides-corporate-updates-announces-workforce-reduction-of-35-ended-2023-in-strong-financial-position-with-175m-in-cash-runway-extended-into-h2-2026

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort ...

 why-faraday-future-shares-are-trading-higher-by-around-14-here-are-20-stocks-moving-premarket

Shares of Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) surged in pre-market trading after the company announced its...

 hc-wainwright--co-maintains-buy-on-ikena-oncology-lowers-price-target-to-11

HC Wainwright & Co. analyst Andres Maldonado maintains Ikena Oncology (NASDAQ:IKNA) with a Buy and lowers the price targ...

 dow-falls-over-200-points-krispy-kreme-reports-downbeat-results

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling over 200 points on Thursday. The Dow traded dow...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION